longevitywatch
HomeMedication
Medication

Rapamycin

Also: sirolimus
Last scientific update: jun 2026

Rapamycin (sirolimus) is a drug that inhibits the protein mTOR, a central switch for growth and aging. In animals it extends lifespan, making it one of the most discussed longevity agents.

Rapamycin at a glance

In animalsExtends lifespanModerate
In humansNot yet provenPreliminary
MechanismInhibits mTOR
UseOff-label, only under supervision

Rapamycin is promising in animals, but in healthy humans it is unproven and not without risk, so experimental.

24 studies4 answersupdated jun 2026
Evidence per claim
Not yet proven for healthy longevity in humans
View evidence →
Preliminary
Works via mTOR, a key route in aging
View evidence →
Moderate
Stimulates autophagy
View evidence →
Preliminary
As uncertain as other candidates such as spermidine
View evidence →
Preliminary
Practical use

For whom

Mainly of interest for research and people following it experimentally through a doctor.

Not for whom

Not meant for self-experiment; there are real side effects and risks.

Usual dose

No proven anti-aging dose in humans; only under medical supervision.

Key caveats

Suppresses the immune system at higher doses; long-term safety in healthy people is unknown.

What we know, and don't

Known

Extends lifespan in several animal species
Inhibits mTOR, a central aging route
Is being seriously studied in humans

Not yet

Whether it extends life in healthy people
The safe dose and frequency
The long-term effects
Common misconceptions
"Rapamycin is a proven anti-aging pill."
Not shown. In humans that is not yet shown.Strong evidence
"It is harmless to try yourself."
False. There are real side effects; only under supervision.Strong evidence
How Rapamycin connects
Related news
A company claims their supplement mix outlives rapamycin in mice, here’s why that needs scrutinyRapamycin may blunt the benefits of exercise in older peopleRapamycin as an anti-aging drug: real human trials are finally coming
Data sources

Wikidata Q411384 · MeSH D020123 · DrugBank DB00877

Newsletter

Stay in the loop

Every two weeks, the most notable longevity research in your inbox. No hype.